ATTENTION NASDAQ: RXST INVESTORS: Contact Berger Montague About an RxSight Class Action Lawsuit
29 juli, 23:11
ATTENTION NASDAQ: RXST INVESTORS: Contact Berger Montague About an RxSight Class Action Lawsuit
PR Newswire
PHILADELPHIA, July 29, 2025
PHILADELPHIA , July 29, 2025 /PRNewswire/ -- Berger Montague PC , a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between November 7, 2024 and July 8, 2025 (the "Class Period").
Investor Deadline: Investors who purchased or acquired RxSight securities during the Class Period may, no later than September 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
RxSight, headquartered in Aliso Viejo, CA , is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).
The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.
On July 8, 2025 , RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."
On this news, RxSight shares fell $4.84 , or 37%, to a close of $7.95 per share on July 9, 2025 .
If you are an RxSight investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago ; Malvern, PA ; Minneapolis ; San Diego ; San Francisco ; Toronto, Canada ; Washington, D.C. , and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
SOURCE Berger Montague
ATTENTION NASDAQ: RXST INVESTORS: Contact Berger Montague About an RxSight Class Action Lawsuit
29 juli, 23:11
ATTENTION NASDAQ: RXST INVESTORS: Contact Berger Montague About an RxSight Class Action Lawsuit
PR Newswire
PHILADELPHIA, July 29, 2025
PHILADELPHIA , July 29, 2025 /PRNewswire/ -- Berger Montague PC , a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between November 7, 2024 and July 8, 2025 (the "Class Period").
Investor Deadline: Investors who purchased or acquired RxSight securities during the Class Period may, no later than September 22, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
RxSight, headquartered in Aliso Viejo, CA , is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).
The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.
On July 8, 2025 , RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."
On this news, RxSight shares fell $4.84 , or 37%, to a close of $7.95 per share on July 9, 2025 .
If you are an RxSight investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague : Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago ; Malvern, PA ; Minneapolis ; San Diego ; San Francisco ; Toronto, Canada ; Washington, D.C. , and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States .
For more information or to discuss your rights, please contact:
Andrew Abramowitz , Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
SOURCE Berger Montague
Handelskrig
Apple
Analys
Handelskrig
Mest läst
Apple
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
